List of questions

A
AirsonettWorkshop language: English
  • 1591

    How/what can we do to earlier detect and initiate adequate treatment of asthma and allergy, to prevent progression of these diseases?


    The significance of particles for astma and allergy development is important, but is not taken seriously enough. Preventive care and treatment in an early stage of disease should be prioritized higher, as is written in the treatment guidelines by the Medical Products Agency. Before there were educated allergy advisors all over Sweden, but this is not longer the case.


AstraZenecaWorkshop language: English
  • 1598

    Are cells from asthmatic & COPD airways deficient in their intracellular sensing and activation of immunity response?


    Viral respiratory tract infections are responsible for a major part of asthma & Chronic Obstructive Pulmonary Disease (COPD) exacerbations, with the most severe requiring hospitalization. Exacerbations and worsening of the diseases are a major cost to healthcare in respiratory diseases. Infections can trigger severe asthma exacerbations even when there is good asthma or COPD control by compliant patients taking optimal doses of inhaled corticosteroids (ICS) or ICS+LABAs (Long-Acting β2-Agonists) and LAMAs (Long-Acting Muscarinic Antagonists). The most common pathogens associated with asthma exacerbations are rhinoviruses, influenza and RSV, which lead to increased lower airway inflammation and increased bronchial responsiveness (ref Johnston et al, AJRCCM, 1996). Asthma patients seem to have an increased susceptibility to RV infection with more severe lower respiratory tract symptoms and reductions in lung function than normal subjects similarly infected (ref Cheung et al, AJRCCM, 1995). The reasons why the asthmatic lower respiratory tract is more susceptible to the effects of infection with RV and cannot clear their airways efficient enough are still unknown.

  • 1618

    The disease COPD shows great variation in both progression and clinically. What possibilities are there to identify different phenotypes of COPD? What phenotypes can provide information about prognosis for disease development? Are there any / some biomarkers that can provide individualized treatment for patients with COPD? May targeting small airway disease offer clinically relevant outcomes, and if so what would be keys to a successful treatment?


    The disease COPD shows great variation in both progression and clinically. What possibilities are there to identify different phenotypes of COPD? What phenotypes can provide information about prognosis for disease development? Are there any / some biomarkers that can provide individualized treatment for patients with COPD? May targeting small airway disease offer clinically relevant outcomes, and if so what would be keys to a successful treatment?

  • 1620

    Is there a need for pediatricians to have an objective tool for differential diagnosis in wheezing children? Is Allergy a relevant factor? What is needed for improvement of asthma outcome in children? What mechanisms are involved in progressing from wheezy kids to develop asthma?


    J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):36-7. doi: 10.1016/j.jaip.2015.11.010. Asthma in Childhood: Expression, Exacerbation, and Progression. Lemanske RF Jr1.


AstraZenecaWorkshop language: English
  • 1601

    What role if any do eosinophils play in COPD?


    Patients with eosinophilic COPD seem to be a distinct subgroup. What is the role of eos in COPD and what charachteristics could be expected from such patient group.

  • 1602

    What is the best biomarker reflecting activated eosinophils


    Biomarkers like plasma EDN associate well with number of blood eosinophils but is sometimes refeered to as a marker of activated eos.


M
McNeil AB (a Johnson & Johnson company)Workshop language: English
  • 1603

    In acute upper respiratory tract infection, the innate mucociliary clearance system can become overloaded and cough clearance of mucus can work to compensate. Would a treatment that was shown to improve mucociliary and cough clearance (e.g. by way of imaging studies utilising a radiolabelled marker) be expected to deliver a meaningful clinical benefit in individuals suffering from acute productive cough due to a simple upper respiratory tract infection (e.g. common cold)?


    In acute upper respiratory tract infection, the innate mucociliary clearance system can become overloaded and cough clearance of mucus can work to compensate. Would a treatment that was shown to improve mucociliary and cough clearance (e.g. by way of imaging studies utilising a radiolabelled marker) be expected to deliver a meaningful clinical benefit in individuals suffering from acute productive cough due to a simple upper respiratory tract infection (e.g. common cold)?


N
Novartis Sverige ABWorkshop language: English
  • 1597

    We are rapidly gaining increased knowledge around different endotypes involved in the pathogenesis of asthma, but the relative contribution of these molecular and cellular pathways to the clinical manifestation of the disease remains unclear. When treating patients with severe asthma, there are now several options for targeted treatments with biologics and non-biologics. How can we ensure improved classification, personalized management, and appropriate treatment evaluation of severe asthma given intertwined biological pathways and often multiple co-existing treatable traits in these patients?


    We are rapidly gaining increased knowledge around different endotypes involved in the pathogenesis of asthma, but the relative contribution of these molecular and cellular pathways to the clinical manifestation of the disease remains unclear. When treating patients with severe asthma, there are now several options for targeted treatments with biologics and non-biologics. How can we ensure improved classification, personalized management, and appropriate treatment evaluation of severe asthma given intertwined biological pathways and often multiple co-existing treatable traits in these patients?

  • 1618

    The disease COPD shows great variation in both progression and clinically. What possibilities are there to identify different phenotypes of COPD? What phenotypes can provide information about prognosis for disease development? Are there any / some biomarkers that can provide individualized treatment for patients with COPD? May targeting small airway disease offer clinically relevant outcomes, and if so what would be keys to a successful treatment?


    The disease COPD shows great variation in both progression and clinically. What possibilities are there to identify different phenotypes of COPD? What phenotypes can provide information about prognosis for disease development? Are there any / some biomarkers that can provide individualized treatment for patients with COPD? May targeting small airway disease offer clinically relevant outcomes, and if so what would be keys to a successful treatment?


O
Olink ProteomicsWorkshop language: English
  • 1606

    How is precision medicine applied to the field of respiratory diseases today? What are the major diagnostic and therapeutic challenges of the respiratory disease field? What is the need for precision medicine in this field, and is it similar in the different diseases? In which respiratory disease does precision medicine have the largest impact today? What biomarkers are used for precision medicine in respiratory diseases today? Is there an unmet need for measurement of protein biomarkers in precision medicine for respiratory diseases?


    n.a.


T
Thermo Fisher ScientificWorkshop language: English
  • 1592

    What allergic disease is believed to cause the highest burden on society and the health care system?


    Asthma, rhinitis, food allergy, atopic dermatitis, etc, are mostly not deadly but affect many and often chronic.


Thermo Fisher ScientificWorkshop language: English
  • 1594

    Could asthma patients be managed more efficiently if there are prognostic tools available for disease activity monitoring?


    Expert Rev Respir Med. 2016 Oct 5:1-11. [Epub ahead of print] Evaluation of monitoring strategies for childhood asthma. Brouwer ML1, Wijngaart LS2, Hugen CA3, Gerrits GP1, Roukema J2, Merkus PJ1,2.

  • 1620

    Is there a need for pediatricians to have an objective tool for differential diagnosis in wheezing children? Is Allergy a relevant factor? What is needed for improvement of asthma outcome in children? What mechanisms are involved in progressing from wheezy kids to develop asthma?


    J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):36-7. doi: 10.1016/j.jaip.2015.11.010. Asthma in Childhood: Expression, Exacerbation, and Progression. Lemanske RF Jr1.